108 related articles for article (PubMed ID: 17111207)
1. Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer.
Rugo H; Shtivelman E; Perez A; Vogel C; Franco S; Tan Chiu E; Melisko M; Tagliaferri M; Cohen I; Shoemaker M; Tran Z; Tripathy D
Breast Cancer Res Treat; 2007 Sep; 105(1):17-28. PubMed ID: 17111207
[TBL] [Abstract][Full Text] [Related]
2. A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer.
Perez AT; Arun B; Tripathy D; Tagliaferri MA; Shaw HS; Kimmick GG; Cohen I; Shtivelman E; Caygill KA; Grady D; Schactman M; Shapiro CL
Breast Cancer Res Treat; 2010 Feb; 120(1):111-8. PubMed ID: 20054647
[TBL] [Abstract][Full Text] [Related]
3. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
4. A Phase 2 study of perifosine in advanced or metastatic breast cancer.
Leighl NB; Dent S; Clemons M; Vandenberg TA; Tozer R; Warr DG; Crump RM; Hedley D; Pond GR; Dancey JE; Moore MJ
Breast Cancer Res Treat; 2008 Mar; 108(1):87-92. PubMed ID: 17458693
[TBL] [Abstract][Full Text] [Related]
5. Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer.
Smith JW; McIntyre KJ; Acevedo PV; Encarnacion CA; Tedesco KL; Wang Y; Asmar L; O'Shaughnessy JA
Breast Cancer Res Treat; 2009 Nov; 118(2):361-7. PubMed ID: 19459042
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
Greco FA; Bonomi P; Crawford J; Kelly K; Oh Y; Halpern W; Lo L; Gallant G; Klein J
Lung Cancer; 2008 Jul; 61(1):82-90. PubMed ID: 18255187
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms underlying selective cytotoxic activity of BZL101, an extract of Scutellaria barbata, towards breast cancer cells.
Fong S; Shoemaker M; Cadaoas J; Lo A; Liao W; Tagliaferri M; Cohen I; Shtivelman E
Cancer Biol Ther; 2008 Apr; 7(4):577-86. PubMed ID: 18305410
[TBL] [Abstract][Full Text] [Related]
10. Weekly paclitaxel in women with heavily pretreated metastatic breast cancer: a retrospective analysis of cases treated at the Chang Gung Memorial Hospital.
Lu CH; Lin YC; Chang HK
Chang Gung Med J; 2007; 30(1):33-40. PubMed ID: 17477027
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
Peschel C; Hartmann JT; Schmittel A; Bokemeyer C; Schneller F; Keilholz U; Buchheidt D; Millan S; Izquierdo MA; Hofheinz RD
Lung Cancer; 2008 Jun; 60(3):374-80. PubMed ID: 18054408
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
[TBL] [Abstract][Full Text] [Related]
13. Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study.
Eichbaum MH; Schuetz F; Khbeis T; Lauschner I; Foerster F; Sohn C; Schneeweiss A
Anticancer Drugs; 2007 Sep; 18(8):963-8. PubMed ID: 17667603
[TBL] [Abstract][Full Text] [Related]
14. A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer.
Blakely LJ; Buzdar A; Chang HY; Frye D; Theriault R; Valero V; Rivera E; Booser D; Kuritani J; Tsuda M
Clin Cancer Res; 2004 Aug; 10(16):5425-31. PubMed ID: 15328180
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
Gomez HL; Doval DC; Chavez MA; Ang PC; Aziz Z; Nag S; Ng C; Franco SX; Chow LW; Arbushites MC; Casey MA; Berger MS; Stein SH; Sledge GW
J Clin Oncol; 2008 Jun; 26(18):2999-3005. PubMed ID: 18458039
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer.
Garin A; Manikhas A; Biakhov M; Chezhin M; Ivanchenko T; Krejcy K; Karaseva V; Tjulandin S
Breast Cancer Res Treat; 2008 Jul; 110(2):309-15. PubMed ID: 17851759
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
Amato RJ; Jac J; Giessinger S; Saxena S; Willis JP
Cancer; 2009 Jun; 115(11):2438-46. PubMed ID: 19306412
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of S-1 in pretreated metastatic breast cancer patients.
Shien T; Shimizu C; Akashi-Tanaka S; Yonemori K; Kohno T; Hojo T; Ando M; Katsumata N; Kinoshita T; Fujiwara Y
Jpn J Clin Oncol; 2008 Mar; 38(3):172-5. PubMed ID: 18296424
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]